Literature DB >> 29575114

American council on ECP (ACE): Why now?

Richard Edelson1, Yanyun Wu2,3, Jennifer Schneiderman4.   

Abstract

Stimulated by the scientific progress in deciphering the principal elements contributing to the clinical efficacy of extracorporeal photochemotherapy (ECP), the American Council on ECP (ACE) was formed, under the auspices of the American Society for Apheresis (ASFA), to develop a field-guiding Consensus Report. ACE is composed of thirty nationally recognized ECP experts, clinically spanning cancer, transplantation, and autoimmunity and scientifically bridging immunology, bioengineering, and hematology. The two-day meeting took place in Manhattan, April 13-14, 2017, and unanimous consensus on nine pivotal points is herein reported. (1) ECP's clinical evolution must now enter a scientifically driven phase. (2) ECP is currently a bidirectional therapy, both immunizing and tolerizing simultaneously, via a single one-size-fits-all inflexible medical device. (3) To preclude inadvertent tolerization in the cancer setting, or immunization in the transplant rejection setting, polarization of ECP to either immunization or tolerization mode to match the clinical need is now possible and necessary. (4) Cutaneous T cell lymphoma (CTCL) is a genetically driven cancer, whose response to ECP is due to enhanced anti-cancer immunity. (5) ECP is a dendritic antigen-presenting cell (DC) based therapy. (6) ECP's efficacy can now be tested in a broad array of cancers. (7) ECP's capacity to tolerize to allotransplants via processing of donor leukocytes merits expedited human investigation. (8) UVA-8-MOP-impacted ECP-induced DC are potent antigen-specific tolerizing agents, while UVA-8-MOP(8-Methoxypsoralen)-spared ECP-induced DC are potent antigen-specific immunizing agents. (9) Six pilot clinical trial areas (CTCL, graft-vs.-host disease, ovarian carcinoma, anti-graft cytotoxic antibodies, pemphigus vulgaris, and haplotype mismatched stem cell transplants) are advised. ACE will be an ongoing advisory group for the field, with the goal of overseeing coordinated clinical and fundamental research efforts.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  ECP; apheresis; cutaneous T cell lymphoma; photopheresis; transplant rejection

Mesh:

Year:  2018        PMID: 29575114     DOI: 10.1002/jca.21627

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  6 in total

Review 1.  Extracorporeal Photopheresis in Graft-versus-Host Disease.

Authors:  Beatrice Drexler; Andreas Buser; Laura Infanti; Gregor Stehle; Joerg Halter; Andreas Holbro
Journal:  Transfus Med Hemother       Date:  2020-05-19       Impact factor: 3.747

2.  Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer.

Authors:  Ayesha B Alvero; Douglas Hanlon; Mary Pitruzzello; Renata Filler; Eve Robinson; Olga Sobolev; Roslyn Tedja; Alessandra Ventura; Marcus Bosenberg; Patrick Han; Richard L Edelson; Gil Mor
Journal:  Oncoimmunology       Date:  2020-05-13       Impact factor: 8.110

Review 3.  Extracorporeal Photopheresis-An Overview.

Authors:  Ara Cho; Christian Jantschitsch; Robert Knobler
Journal:  Front Med (Lausanne)       Date:  2018-08-27

4.  Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept.

Authors:  Céline Coppard; Francis Bonnefoy; Dalil Hannani; Françoise Gabert; Olivier Manches; Joel Plumas; Sylvain Perruche; Laurence Chaperot
Journal:  J Transl Med       Date:  2019-09-18       Impact factor: 5.531

Review 5.  Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions.

Authors:  Brian M Wei; Douglas Hanlon; David Khalil; Patrick Han; Kazuki Tatsuno; Olga Sobolev; Richard L Edelson
Journal:  Yale J Biol Med       Date:  2020-03-27

6.  CD11c+ dendritic cells mediate antigen-specific suppression in extracorporeal photopheresis.

Authors:  H Hackstein; A Kalina; T Jakob; G Bein; B Dorn; I S Keil; N Baal; G Michel; C Brendel; A Neubauer
Journal:  Clin Exp Immunol       Date:  2020-11-08       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.